221 related articles for article (PubMed ID: 20189777)
1. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?
Roberts JA; Hope WW; Lipman J
Int J Antimicrob Agents; 2010 May; 35(5):419-20. PubMed ID: 20189777
[No Abstract] [Full Text] [Related]
2. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
Roberts JA; Ulldemolins M; Roberts MS; McWhinney B; Ungerer J; Paterson DL; Lipman J
Int J Antimicrob Agents; 2010 Oct; 36(4):332-9. PubMed ID: 20685085
[TBL] [Abstract][Full Text] [Related]
3. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia.
Hayashi Y; Lipman J; Udy AA; Ng M; McWhinney B; Ungerer J; Lust K; Roberts JA
Int J Antimicrob Agents; 2013 Feb; 41(2):162-6. PubMed ID: 23153962
[TBL] [Abstract][Full Text] [Related]
4. Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations.
Burkhardt O; Kumar V; Schmidt S; Kielstein JT; Welte T; Derendorf H
Int J Antimicrob Agents; 2010 Jan; 35(1):96-7. PubMed ID: 19896806
[No Abstract] [Full Text] [Related]
5. Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?
Delattre IK; Taccone FS; Jacobs F; Hites M; Dugernier T; Spapen H; Laterre PF; Wallemacq PE; Van Bambeke F; Tulkens PM
Expert Rev Anti Infect Ther; 2017 Jul; 15(7):677-688. PubMed ID: 28571493
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study.
Patel BM; Paratz J; See NC; Muller MJ; Rudd M; Paterson D; Briscoe SE; Ungerer J; McWhinney BC; Lipman J; Roberts JA
Ther Drug Monit; 2012 Apr; 34(2):160-4. PubMed ID: 22406650
[TBL] [Abstract][Full Text] [Related]
7. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
[TBL] [Abstract][Full Text] [Related]
8. Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome.
Sádaba B; Azanza JR; Campanero MA; García-Quetglas E
Clin Microbiol Infect; 2004 Nov; 10(11):990-8. PubMed ID: 15522002
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics.
Mohd Hafiz AA; Staatz CE; Kirkpatrick CM; Lipman J; Roberts JA
Minerva Anestesiol; 2012 Jan; 78(1):94-104. PubMed ID: 21730935
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.
Roberts JA; Paratz J; Paratz E; Krueger WA; Lipman J
Int J Antimicrob Agents; 2007 Jul; 30(1):11-8. PubMed ID: 17442541
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.
Veiga RP; Paiva JA
Crit Care; 2018 Sep; 22(1):233. PubMed ID: 30244674
[TBL] [Abstract][Full Text] [Related]
12. Augmented renal clearance and therapeutic monitoring of β-lactams.
Udy AA; De Waele JJ; Lipman J
Int J Antimicrob Agents; 2015 Apr; 45(4):331-3. PubMed ID: 25665727
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
[TBL] [Abstract][Full Text] [Related]
14. [Beta-lactam antibiotics].
Suárez C; Gudiol F
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):116-29. PubMed ID: 19254642
[TBL] [Abstract][Full Text] [Related]
15. Use of high-performance liquid chromatography (HPLC) to monitor beta-lactam plasma concentrations during the treatment of endocarditis.
Tattevin P; Tribut O; Arvieux C; Dupont M; Flicoteaux R; Desbordes L; Le Tulzo Y; Michelet C
Clin Microbiol Infect; 2005 Jan; 11(1):76-9. PubMed ID: 15649311
[TBL] [Abstract][Full Text] [Related]
16. Reply to Rhodes et al.
Roberts JA; Paul SK; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J
Clin Infect Dis; 2014 Sep; 59(6):907-8. PubMed ID: 24867785
[No Abstract] [Full Text] [Related]
17. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization.
Sime FB; Udy AA; Roberts JA
Curr Opin Pharmacol; 2015 Oct; 24():1-6. PubMed ID: 26119486
[TBL] [Abstract][Full Text] [Related]
18. Editorial commentary: Are blood concentrations enough for establishing pharmacokinetic/pharmacodynamic relationships?
Craig WA
Clin Infect Dis; 2014 Apr; 58(8):1084-5. PubMed ID: 24470275
[No Abstract] [Full Text] [Related]
19. Conclusions. Role of the oral Beta-lactams in the treatment of exacerbations of chronic bronchitis: critical analysis and therapeutics recommendations.
Blasi F; Concia E; Mazzei T; Moretti AM; Nicoletti G; Novelli A; Tempera G;
J Chemother; 2010 Nov; 22 Suppl 1():25-8. PubMed ID: 21097390
[No Abstract] [Full Text] [Related]
20. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes.
Rhodes NJ; MacVane SH; Kuti JL; Scheetz MH
Clin Infect Dis; 2014 Sep; 59(6):905-7. PubMed ID: 24867788
[No Abstract] [Full Text] [Related]
[Next] [New Search]
